Peter Flachenecker

5.9k total citations · 1 hit paper
118 papers, 3.4k citations indexed

About

Peter Flachenecker is a scholar working on Pathology and Forensic Medicine, Neurology and Psychiatry and Mental health. According to data from OpenAlex, Peter Flachenecker has authored 118 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Pathology and Forensic Medicine, 29 papers in Neurology and 23 papers in Psychiatry and Mental health. Recurrent topics in Peter Flachenecker's work include Multiple Sclerosis Research Studies (91 papers), Fibromyalgia and Chronic Fatigue Syndrome Research (20 papers) and Peripheral Neuropathies and Disorders (20 papers). Peter Flachenecker is often cited by papers focused on Multiple Sclerosis Research Studies (91 papers), Fibromyalgia and Chronic Fatigue Syndrome Research (20 papers) and Peripheral Neuropathies and Disorders (20 papers). Peter Flachenecker collaborates with scholars based in Germany, Austria and Spain. Peter Flachenecker's co-authors include Peter Rieckmann, Uwe K. Zettl, Klaus V. Toyka, Karlheinz Reiners, T. Henze, M. Gottschalk, Tania Kümpfel, Oliver Grauer, Claudia Trenkwalder and Boris Kallmann and has published in prestigious journals such as SHILAP Revista de lepidopterología, Brain and Neurology.

In The Last Decade

Peter Flachenecker

110 papers receiving 3.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters

2002 505 citations Peter Flachenecker, Peter Rieckmann et al. Multiple Sclerosis Journal profile →

Peers

Countries citing papers authored by Peter Flachenecker

Since Specialization

Citations

This map shows the geographic impact of Peter Flachenecker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Flachenecker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Flachenecker more than expected).

Fields of papers citing papers by Peter Flachenecker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Flachenecker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Flachenecker. The network helps show where Peter Flachenecker may publish in the future.

Co-authorship network of co-authors of Peter Flachenecker

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Flachenecker. A scholar is included among the top collaborators of Peter Flachenecker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Flachenecker. Peter Flachenecker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Age-related differences in switching highly effective disease-modifying therapy in patients with multiple sclerosis 2025 ·Journal of Neurology ·David Ellenberger, Niklas Frahm, Alexander Stahmann, Clemens Warnke, (unknown), Christoph Kleinschnitz, Peter Flachenecker, (unknown), Matthias Grothe, Uwe K. Zettl	0
2	Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry 2024 ·Therapeutic Advances in Neurological Disorders ·Niklas Frahm, David Ellenberger, Alexander Stahmann, (unknown), (unknown), (unknown), (unknown), (unknown), Peter Flachenecker, Christoph Kleinschnitz, Friedemann Paul, Dagmar Krefting, Uwe K. Zettl, (unknown), Clemens Warnke	3
3	The impact of bladder problems on well-being in multiple sclerosis – A cross-sectional study 2024 ·Multiple Sclerosis and Related Disorders ·Sabrina Islamoska, (unknown), Jalesh N. Panicker, Peter Flachenecker, V. Phé, Giampaolo Brichetto, Bertil Blok, Kim Bundvig Barken	1
4	Translation and validation of the multiple sclerosis walking scale 12 for the German population – the MSWS-12/D 2023 ·Health and Quality of Life Outcomes ·(unknown), (unknown), Judith Bellmann–Strobl, Peter Flachenecker, Insa Schiffmann, (unknown), (unknown), (unknown), (unknown), Ludwig Rasche, (unknown), Christoph Heesen, Friedemann Paul, Jan‐Patrick Stellmann, Tanja Schmitz‐Hübsch	5
5	Comparison of employment among people with Multiple Sclerosis across Europe 2022 ·Multiple Sclerosis Journal - Experimental Translational and Clinical ·David Ellenberger, Tina Parciak, Waldemar Brola, Jan Hillert, Rod Middleton, Alexander Stahmann, Christoph Thalheim, Peter Flachenecker	6
6	Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS Registry 2022 ·Neurology and Therapy ·Niklas Frahm, (unknown), David Ellenberger, Peter Flachenecker, Friedemann Paul, Clemens Warnke, Christoph Kleinschnitz, Tina Parciak, Dagmar Krefting, Kerstin Hellwig, Judith Haas, Paulus Rommer, Alexander Stahmann, Uwe K. Zettl	3
7	Clinical Predictors of Neurogenic Lower Urinary Tract Dysfunction in Persons with Multiple Sclerosis 2022 ·Diagnostics ·(unknown), (unknown), (unknown), (unknown), (unknown), Albert Kaufmann, Wolfgang Feneberg, (unknown), Peter Flachenecker, T. Henze, (unknown), Paul Schmidt, (unknown), (unknown), Ruth Kirschner‐Hermanns, Stephanie C. Knüpfer	8
8	Das autonome Nervensystem 2022 ·Ralf Baron, Frank Birklein, Peter Flachenecker, Janne Gierthmühlen, W. Jänig, (unknown), Wolfgang H. Jost, Gerhard J. Jungehülsing, (unknown), (unknown), H. Krammer, (unknown), Winfried Neuhuber, Tanja Schlereth, Hans-Peter Seelig, (unknown), Joachim Weis	0
9	Managing neuropsychological impairment in multiple sclerosis – Controlled study on a standardized metacognitive intervention (MaTiMS) 2022 ·Multiple Sclerosis and Related Disorders ·Jana Pöttgen, Tim Friede, Stephanie Lau, Stefan M. Gold, (unknown), (unknown), Peter Flachenecker, Christoph Heesen, Iris‐Katharina Penner	9
10	Chances and challenges of a long-term data repository in multiple sclerosis: 20th birthday of the German MS registry 2021 ·Scientific Reports ·(unknown), David Ellenberger, Peter Flachenecker, Tim Friede, Judith Haas, Kerstin Hellwig, Tina Parciak, Clemens Warnke, Friedemann Paul, Uwe K. Zettl, Alexander Stahmann	30
11	Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry 2021 ·Multiple Sclerosis Journal ·Stefan Blaschke, David Ellenberger, Peter Flachenecker, Kerstin Hellwig, Friedemann Paul, Dieter Pöhlau, Christoph Kleinschnitz, Paulus Rommer, Maria Adele Rueger, Uwe K. Zettl, Alexander Stahmann, Clemens Warnke	9
12	Validity of Consumer Activity Monitors and an Algorithm Using Smartphone Data for Measuring Steps during Different Activity Types 2020 ·International Journal of Environmental Research and Public Health ·Verena Hartung, (unknown), (unknown), (unknown), Asarnusch Rashid, (unknown), (unknown), Mathias Mäurer, Peter Flachenecker, Klaus Pfeifer, Alexander Tallner	23
13	Neues zur symptomatischen MS-Therapie: Teil 5 – Fatigue 2017 ·Der Nervenarzt ·T. Henze, Wolfgang Feneberg, Peter Flachenecker, D. Seidel, H. Albrecht, M. Starck, Sven G. Meuth	8
14	Development and pilot phase of a European MS register 2010 ·Journal of Neurology ·Peter Flachenecker, Laura Khil, (unknown), (unknown), (unknown), Francisco Pérez‐Miralles, Jaume Sastre‐Garriga, Thomas Zwingers	8
15	Aktive Schutzimpfungen bei multipler Sklerose 2008 ·DMW - Deutsche Medizinische Wochenschrift ·Peter Flachenecker, (unknown), Hans‐Peter Hartung	2
16	sICAM-1 is not a marker for disease activity in the relapse-free interval of multiple sclerosis - a cross-sectional pilot study 2002 ·Journal of Neurology ·Peter Flachenecker, Stefan Jung, Peter Rieckmann, Klaus V. Toyka	3
17	Comment on the contribution by F. Zipp and K. P. Wandinger. Current recommendations for vaccinations in multiple sclerosis 2001 ·Der Nervenarzt ·Peter Rieckmann, (unknown), Peter Flachenecker, Klaus V. Toyka	1
18	Herzrhythmusstörungen beim Guillain-Barré-Syndrom Eine Übersicht zur Diagnostik einer seltenen, aber potenziell lebensbedrohlichen Komplikation 2001 ·Der Nervenarzt ·Peter Flachenecker, Klaus V. Toyka, Karlheinz Reiners	7
19	Clinical outcome of sural nerve biopsy: a retrospective study 1999 ·Journal of Neurology ·Peter Flachenecker, (unknown), Roland Goldbrunner, Klaus V. Toyka	19
20	Quantitative assessment of cardiovascular autonomic function in Guillain‐Barré syndrome 1997 ·Annals of Neurology ·Peter Flachenecker, (unknown), Hans‐Peter Hartung, Karlheinz Reiners	54

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact